SCHEMBL5773578

SCHEMBL5773578

CSc1ccc(-c2oncc2CO)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 1/20 0.36
GCGR P47871 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
SLC22A12 Q96S37 1/20 0.35
CYP19A1 P11511 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PPARA Q07869 1/20 0.33
TDO2 P48775 1/20 0.33
PTGS2 P35354 3/20 0.33
HAO1 Q9UJM8 1/20 0.33
ADORA3 P0DMS8 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA2B P29275 1/20 0.32
ADORA1 P30542 1/20 0.32
NISCH Q9Y2I1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5776652 0.85 SIRT2 (0.34) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL5773431 0.80 FFAR4 (0.45) SLC22A12CYP2C19PPARAPTGS2HAO1
SCHEMBL5774121 0.78 TDO2 (0.47) MAPK14MEN1KMT2ACYP19A1CYP2C9
SCHEMBL5775491 0.78 PPARA (0.45) MEN1KMT2ACYP19A1CYP2C9CYP2C19
SCHEMBL5775970 0.78 TDO2 (0.51) MEN1KMT2APPARATDO2KDM4E
SCHEMBL5772173 0.78 TDO2 (0.55) MEN1KMT2APPARATDO2KDM4E
SCHEMBL5775254 0.77 MEN1 (0.56) MEN1KMT2ACYP19A1CYP2C9CYP2C19
SCHEMBL5773233 0.77 CCNC (0.41) MEN1KMT2ASLC22A12PPARAPTGS2
SCHEMBL8836686 0.76 MAPK14 (0.47) MAPK13GCGRMAPK12MAPK11MAPK14
SCHEMBL5776001 0.72 MEN1 (0.37) MEN1KMT2ACYP19A1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1719761-A1 NOVEL HETEROCYCLIC COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2006-11-08 EP disclosed
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR MAPK13 892/4885GCGR 33/4885MAPK12 1368/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 MAPK13 1574/4885GCGR 25/4885MAPK12 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.